{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:11:16Z","timestamp":1771510276917,"version":"3.50.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,25]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>A paradoxical reaction refers to a response opposite to the expected effects of drug therapy. Cutaneous paradoxical reactions, which occur with the use of immunosuppressive drugs, are believed to result from treatment-induced cytokine imbalances. These reactions can manifest as various dermatological conditions, including psoriasis and palmoplantar pustulosis. Currently, no established guidelines exist for reducing or discontinuing biologics in patients with rheumatoid arthritis who experience paradoxical reactions, posing a significant challenge for clinicians managing dermatitis and the underlying diseases. This case report presents two cases of patients with rheumatoid arthritis who developed palmoplantar pustulosis as a paradoxical reaction after treatment with golimumab, a tumour necrosis factor inhibitor. Both patients achieved remission of joint and skin symptoms following treatment with peficitinib, a Janus kinase inhibitor. To the best of our knowledge, this is the first report documenting the successful treatment of paradoxical reaction-induced palmoplantar pustulosis with peficitinib. These findings suggest that peficitinib could serve as an effective alternative when tumour necrosis factor inhibitors are no longer viable. Thus, peficitinib may be a potential therapeutic option for the management of rheumatoid arthritis patients with palmoplantar pustulosis.<\/jats:p>","DOI":"10.1093\/mrcr\/rxaf080","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T13:24:16Z","timestamp":1763731456000},"source":"Crossref","is-referenced-by-count":0,"title":["Case reports: Peficitinib efficacy in treating palmoplantar pustulosis induced by paradoxical reactions to golimumab in two rheumatoid arthritis cases"],"prefix":"10.1093","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3927-399X","authenticated-orcid":false,"given":"Mari","family":"Yamamoto","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Nephrology, Chubu Rosai Hospital , Nagoya ,","place":["Japan"]},{"name":"Infection Control Team, Chubu Rosai Hospital , Nagoya ,","place":["Japan"]},{"name":"Scientific Research WorkS Peer Support Group (SRWS-PSG) , Osaka ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5228-6299","authenticated-orcid":false,"given":"Waka","family":"Yokoyama-Kokuryo","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Nephrology, Chubu Rosai Hospital , Nagoya ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1395-7062","authenticated-orcid":false,"given":"Hiroki","family":"Ikai","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Nephrology, Chubu Rosai Hospital , Nagoya ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5189-9584","authenticated-orcid":false,"given":"Tsuyoshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Nephrology, Chubu Rosai Hospital , Nagoya ,","place":["Japan"]},{"name":"Infection Control Team, Chubu Rosai Hospital , Nagoya ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3744-3537","authenticated-orcid":false,"given":"Naoho","family":"Takizawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Nephrology, Chubu Rosai Hospital , Nagoya ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3688-0636","authenticated-orcid":false,"given":"Yoshiro","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Nephrology, Chubu Rosai Hospital , Nagoya ,","place":["Japan"]},{"name":"Infection Control Team, Chubu Rosai Hospital , Nagoya ,","place":["Japan"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"2026021908112696400_ref1","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.autrev.2009.10.003","article-title":"Autoimmune diseases induced by biological agents: a double-edged sword?","volume":"9","author":"Ramos-Casals","year":"2010","journal-title":"Autoimmun Rev"},{"key":"2026021908112696400_ref2","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.jaad.2020.12.010","article-title":"Paradoxical eruptions to targeted therapies in dermatology: a systematic review and analysis","volume":"86","author":"Murphy","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2026021908112696400_ref3","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/jum.16527","article-title":"Contribution of musculoskeletal ultrasound in the diagnosis of seronegative rheumatoid arthritis","volume":"43","author":"Cen","year":"2024","journal-title":"J Ultrasound Med"},{"key":"2026021908112696400_ref4","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"Brown","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2026021908112696400_ref5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1345\/aph.1K271","article-title":"Methotrexate-induced papular eruption following treatment of psoriasis","volume":"42","author":"Mebazaa","year":"2008","journal-title":"Ann Pharmacother"},{"key":"2026021908112696400_ref6","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/ard.2010.147272","article-title":"Differential diagnosis between rheumatoid arthritis and psoriatic arthritis: the value of ultrasound findings at metacarpophalangeal joints level","volume":"70","author":"Gutierrez","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026021908112696400_ref7","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.13352","article-title":"Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study","volume":"42","author":"Pugliese","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"2026021908112696400_ref8","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3389\/fphar.2019.00282","article-title":"Paradoxical skin reactions to biologics in patients with rheumatologic disorders","volume":"10","author":"Garcovich","year":"2019","journal-title":"Front Pharmacol"},{"key":"2026021908112696400_ref9","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jaad.2018.12.018","article-title":"TNF-\u03b1 inhibitor-induced psoriasis: a decade of experience at the Cleveland Clinic","volume":"83","author":"Mazloom","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026021908112696400_ref10","doi-asserted-by":"crossref","first-page":"e15713","DOI":"10.1111\/dth.15713","article-title":"Recalcitrant and persistent adalimumab-induced paradoxical psoriasiform skin reaction in a rheumatoid arthritis patient successfully treated with upadacitinib","volume":"35","author":"Zabotti","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026021908112696400_ref11","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.36849\/JDD.7645","article-title":"A case series of TNF inhibitor-induced psoriasis successfully treated with upadacitinib","volume":"23","author":"Woodbury","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"2026021908112696400_ref12","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.2147\/IDR.S421299","article-title":"Refractory palmoplantar pustulosis successfully treated with JAK inhibitor tofacitinib: a case series","volume":"16","author":"Xu","year":"2023","journal-title":"Infect Drug Resist"},{"key":"2026021908112696400_ref13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jdcr.2019.03.024","article-title":"Palmoplantar pustulosis-like eruption following tofacitinib therapy for juvenile idiopathic arthritis","volume":"5","author":"Shibata","year":"2019","journal-title":"JAAD Case Rep"},{"key":"2026021908112696400_ref14","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data","volume":"13","author":"Harrington","year":"2020","journal-title":"J Inflamm Res"},{"key":"2026021908112696400_ref15","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1093\/rheumatology\/kead448","article-title":"Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases","volume":"63","author":"Taylor","year":"2024","journal-title":"Rheumatology."},{"key":"2026021908112696400_ref16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/bjd.13745","article-title":"A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"2026021908112696400_ref17","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/jamadermatol.2024.2701","article-title":"Tyrosine kinase 2 inhibition with Zasocitinib (TAK-279) in psoriasis: a randomized clinical trial","volume":"160","author":"Armstrong","year":"2024","journal-title":"JAMA Dermatol"},{"key":"2026021908112696400_ref18","doi-asserted-by":"crossref","first-page":"1476584","DOI":"10.3389\/fimmu.2025.1476584","article-title":"Case report: successful management of refractory palmoplantar pustulosis with upadacitinib","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"2026021908112696400_ref19","doi-asserted-by":"crossref","first-page":"112762","DOI":"10.1016\/j.intimp.2024.112762","article-title":"Janus kinase inhibitor tofacitinib successfully treated palmoplantar pustulosis after switching from secukinumab: a case report and review of the literature","volume":"139","author":"Fan","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"2026021908112696400_ref20","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxaf080\/65491788\/rxaf080.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf080\/65491788\/rxaf080.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/9\/2\/rxaf080\/65491788\/rxaf080.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:11:37Z","timestamp":1771506697000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxaf080\/8341479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,7,25]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxaf080","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025]]},"published":{"date-parts":[[2025]]},"article-number":"rxaf080"}}